How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria: the 2013 revision and update. Allergy 2014;69:868–887.
   PubMed Web of Science ®Google Scholar
• O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197–201.
   PubMed Web of Science ®Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 2019. doi: 10.1111/all.14037.
   PubMedGoogle Scholar
• Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol 2019;10:627.
   PubMed Web of Science ®Google Scholar
• Akelma AZ, Mete E, Cizmeci MN, et al. The role of mean platelet volume as an inflammatory marker in children with chronic spontaneous urticaria. Allergol Immunopathol 2015;43:10–13.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2017;31:964–971.
   PubMed Web of Science ®Google Scholar
• Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol 2013;161:197–204.
   PubMed Web of Science ®Google Scholar
• Asero R. D-dimer: a biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol 2013;132:983–986.
   PubMed Web of Science ®Google Scholar
• Altrichter S, Boodstein N, Maurer M. Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy 2009;64:652–656.
   PubMed Web of Science ®Google Scholar
• Grzanka A, Machura E, Misiolek M, et al. Systemic inflammatory response and calcification markers in patients with long lasting moderate-severe chronic spontaneous urticaria. Eur J Dermatol 2015;25:26–28.
   PubMed Web of Science ®Google Scholar
• Acer E, Kaya Erdogan H, Yüksel Çanakçı N, et al. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol 2019;38:5–8.
   PubMed Web of Science ®Google Scholar
• Gruchała A, Cisłak A, Golański J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as an alternative to C-reactive protein in diagnostics of inflammatory state in patients with psoriasis. Our Dermatol Online 2019;10:7–11.
   Google Scholar
• An I, Ucmak D, Ozturk M. Evaluation of neutrophil-tolymphocyte ratio, platelet-tolymphocyte ratio and mean platelet volume in patients with lichen planus. Ann Med Res 2019;26:161–164.
   Google Scholar
• Ertaş R, Özyurt K, Karakükçü Ç, et al. Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria. Turk J Med Sci 2018;48:1255–1262.
   PubMed Web of Science ®Google Scholar
• Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337–342.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869–873.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Marzano AV, et al. The role of platelets in chronic urticaria. Int Arch Allergy Immunol 2016;169:71–79.
   PubMed Web of Science ®Google Scholar
• Isiksacan N, Koser M, Cemsitoglu F, et al. Platelet and other hemostatic characteristics in patients with chronic urticaria. Angiology 2015;66:387–391.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017;72:519–533.
   PubMed Web of Science ®Google Scholar
• Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol 2018;20:476–483.
   PubMed Web of Science ®Google Scholar
• Shimura T, Shibata M, Gonda K, et al. Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer. Biomed Rep 2016;5:203–207.
   PubMed Web of Science ®Google Scholar
• Abderrazak A, Couchie D, Mahmood DF, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2. Ki mice fed a high-fat diet. Circulation 2015;131:1061–1070.
   PubMed Web of Science ®Google Scholar
• Karabay EA, Cerman AA, Altunay İK. Serum C-reactive protein, neutrophil-lymphocyte ratio and uric acid levels in chronic spontaneous urticaria. Turkiye Klin J Dermatol 2016;26:125–131.
   Google Scholar
• Sarac G, Mantar İ, Sener S, et al. Assessment of change in neutrophil-lymphocyte ratio, platelet-lymphocyteratio in patients with acute and chronic urticaria. Ann Med Res 2018;25:719–722.
   Google Scholar
• Aleem S, Masood Q, Hassan I. Correlation of mean platelet volume levels with severity of chronic urticaria. J Dermatol Dermatol Surg 2015;19:9–14.
   Web of Science ®Google Scholar
• Magen E, Mishal J, Zeldin Y, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010;339:504–508.
   PubMed Web of Science ®Google Scholar
• Kasperska-Zając A, Grzanka A, Jarzab J, et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int 2014;2014:650913.
   PubMed Web of Science ®Google Scholar
• Huang Y, Deng W, Zheng S, et al. Relationship between monocytes to lymphocytes ratio and axial spondyloarthritis. Int Immunopharmacol 2018;57:43–46.
   PubMed Web of Science ®Google Scholar
• Xiang J, Zhou L, Li X, et al. Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. Transl Oncol 2016;10:33–39.
   PubMed Web of Science ®Google Scholar
• Song S, Li C, Li S, et al. Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer. Ott 2017;10:3145–3154.
   Google Scholar
• Jiang Y, Zang M, Li S. Serum PLR and LMR in Behçet's disease: can they show the disease activity? Medicine (Baltimore) 2017;96:e6981.
   PubMed Web of Science ®Google Scholar
• Çildağ S, Şentürk T. The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Pdia 2018;35:516–519.
   Google Scholar
• Banh HL, Trevoy J, Pabst H, et al. Persistent elevation of pe- ripheral blood myeloid cell counts associated with omalizumab therapy. Am J Health Syst Pharm 2012;69:302–306.
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:869–873.
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016;71:1135–1144.
   PubMed Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in CSU patients is linked to and predicted by IgE levels and their change. Allergy 2018;73:705–712.
   PubMed Web of Science ®Google Scholar
• Straesser MD, Oliver D, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract 2018;6:1386–1388.
   PubMed Web of Science ®Google Scholar
• Weller K, Ohanyan T, Hawro T, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy 2018;73:2406–2408.
   PubMed Web of Science ®Google Scholar
• Deza G, Bertolín-Colilla M, Sánchez S, et al. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol 2018;141:2313–2316.
   PubMed Web of Science ®Google Scholar
• Tamer F, Gulru Erdogan F, Dincer Rota D, et al. Efficacy of omalizumab in patients with chronic spontaneous urticaria and its association with serum IgE levels and eosinophil count. Acta Dermatovenerol Croat 2019;27:101–106.
   PubMed Web of Science ®Google Scholar